DIAGNOSTIC VALUE OF TUMOR MARKER CA-125 IN THE EARLY DIAGNOSIS OF OVARIAN CANCER
Main Article Content
Abstract
Objective – to determine the diagnostic significance of the cancer marker CA-125 in the early stages of ovarian malignancy, its sensitivity and specificity.
Materials and methods. A retrospective analysis of the medical histories of 44 women operated in gynecological hospitals of the General network with neoplasms in the area of the uterus appendages for the period from 2016 to 2019 was carried out. Ovarian neoplasms in women were detected on an outpatient basis during gynecological examination in the Kemerovo city clinical hospital N 4 women's consultation, confirmed by ultrasound. All women were assessed for baseline CA-125 in the scope of a comprehensive preoperative examination. Blood was taken from a vein, in the morning, on an empty stomach, on the 2-3 day of the menstrual cycle, in postmenopausal women on any day. The recommended threshold level for CA-125 is less than 35 IU/ml.
Statistical data analysis was performed using the Microsoft Office Excel 2010 application software package (license agreement 7401764000001067177) and Stat Soft Statistica 6.1 (license agreement BXXR006D092218FAN11). After receiving the results of the study, sensitivity, specificity, and predictive value were determined for CA 125. The results of the study were processed using Statistics Trial and Microsoft Excel.
Results. At the outpatient stage, 33 (75 %) women had a normal CA score of 125, 11 (25 %) – higher than the norm. Excess of CA-125 twice or more was diagnosed in 7 (16 %) women. In connection with its increase, the patients were consulted by an oncologist.
After surgical treatment in various volumes, the results of the histological study were presented with Brenner's tumor in 2 %, serous adenocarcinoma in 7 %, endometrioid cyst in 9 %, follicular cyst in 9 %, Mature teratoma in 11 %, tecoma in 11 %, fibroma in 16 %, and serous cystadenoma in 34 %. When comparing the results of CA-125 and morphological diagnosis, matches were found in 45 % of cases. Specificity was 75 %, sensitivity – 80 %.
Conclusion. Thus, based on the data from our study, the determination of the tumor-associated CA-125 antigen is not a strictly specific screening marker for early diagnosis of ovarian cancer.
Keywords
Article Details
Information about financing and conflict of interests
The authors declare that they have no apparent or potential conflicts of interest related to the publication of this article.
This work is licensed under a Creative Commons Attribution 4.0 License.
How to Cite
References
Axel EM. Morbidity and mortality due to malignant neoplasms of the female reproductive system in Russia. Oncogynecology. 2015; 1: 6-15. Russian (Аксель Е.М. Заболеваемость и смертность от злокачественных новообразований органов женской репродуктивной системы в России //Онкогинекология. 2015. № 1. С. 6-15)
Diagnosis and treatment of benign ovarian neoplasms from the position of cancer prevention (treatment protocol): clinical recommendations of Ministry of health of the Russian from 04.12. 2018 N 15-4/10/2-7838. 44 p.) Russian (Диагностика и лечение доброкачественных новообразований яичников с позиции профилактики рака (протокол лечения): Клин. реком. МЗ РФ от 04.12. 2018 N 15-4/10/2-7838. 44 с.)
Lyubchenko LN, Bateneva EI. Medical genetic coun-seling and DNA testing when hereditary predisposition to breast and ovarian cancer. М., 2014. 75 p. Russian (Любченко Л.Н., Батенева Е.И. Медико-генетический анализ и ДНК-тестирование при наследственной предрасположенности к раку молочной железы и яичников. М., 2014. 75 с.)
Rebbeck TR. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum Mutat. 2018; 39(5): 593-620
Robson ME et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol. 2015; 28: 893-901
Daly MB et al. NCCN Guidelines Insights: Genetic /Familial High-Risk Assessment: Breast and Ovarian, Version 2. 2017. J Natl Compr Canc Netw. 2017; 15: 9-20
Hartmann LN, Lindor NM. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Eng J Med. 2016; 374: 454-468
Elgina SI, Zolotarevskaya OS, Zakharov IS, Mozes VG, Rudaeva EV, Razumovа VA, Kratovskiy AY. Cytological screening in the diagnosis of cervical cancer. Mother and Baby in Kuzbass. 2019; 3: 37-40. Russian (Елгина С.И., Золоторевская О.С. Захаров И.С., Мозес В.Г., Рудаева Е.В., Разумова В.А., Кратовский А.Ю. Цитологичекий скрининг в диагностике рака шейки матки //Мать и Дитя в Кузбассе. 2019. № 3. С. 37-40)
Committee Opinion No. 716. American College of Obstetricians and Gynecologists. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol. 2017; 130(3): e146–e149. DOI: 10.1097/AOG.0000000000002299
Efimova OA. Complex radiodiagnosis of ovarian tumors. Oncology Bulletin of the Volga region. 2017; 3(30): 61-64. Russian (Ефимова О.А. Комплексная лучевая диагностика опухолевых образований яичников на дооперационном этапе //Поволжский онкологический вестник. 2017. № 3(30). С. 60-63)
Ionescu CA, Matei A, Navolan D et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses. Medicine (Baltimore). 2018; 97(31): e11762
Querleu D, Planchamp F, Chiva L et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. Int J Gynecol Cancer. 2017; 27(7): 1534-1542
Capriglione S, Luvero D, Plotti F et al. Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature. Med Oncol. 2017; 34(9): 164
Chen F, Shen J, Wang J et al. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res. 2018; 10: 1313-1318